Fig. 2From: Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysisPooled risk of HBVr among cancer patients with ICIs treatment. HBVr hepatitis B virus reactivation, ICIs immune checkpoint inhibitors, ES effect size, CI confidence intervalBack to article page